Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
January 05 2022 - 7:01AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare
company, today announced Chairman and Chief Executive
Officer Al Altomari will present at the H.C. Wainwright
BioConnect Virtual Conference taking place January 10-13, 2022, and
at Biotech Showcase taking place January 10-12, 2022.
Details of the presentations are as follows:
Event: |
H.C. Wainwright BioConnect
Virtual Conference |
Date: |
January 10-13, 2022 |
Time: |
Presentation available
on-demand starting at 7:00 a.m., ET on January 10, 2022 |
|
|
Event: |
Biotech Showcase |
Date: |
January 10-12, 2022 |
Time: |
Presentation available
on-demand starting at 11:00 a.m., ET on January 10, 2022 |
The presentations will be accessible in the investor relations
section of the Agile Therapeutics website here.
About Agile Therapeutics, Inc.Agile
Therapeutics is a women's healthcare company dedicated to
fulfilling the unmet health needs of today’s women. Our
product and product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our initial
product, Twirla®, (levonorgestrel and ethinyl estradiol)
transdermal system, is a non-daily prescription contraceptive.
Twirla is based on our proprietary transdermal patch technology,
called Skinfusion®, which is designed to allow drug delivery
through the skin. For more information, please visit the company
website at www.agiletherapeutics.com. The
Company may occasionally disseminate material, nonpublic
information on the Company’s website.
Forward-Looking StatementCertain information
contained in this press release includes “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. We may in some cases use terms such as
“predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “likely,” “will,” “should” or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are
based on current beliefs and expectations of our management team
that involve risks, potential changes in circumstances,
assumptions, and uncertainties, including statements regarding our
ongoing and planned manufacturing and commercialization of Twirla®,
the potential market acceptance and uptake of Twirla, including the
increasing demand for Twirla, our results of operations, revenues,
financial condition, liquidity, prospects, growth and strategies,
the expected benefits of our marketing and sales distribution
strategies, current and future Medicare coverage for Twirla, and
the development of our other potential product candidates. Any
or all of the forward-looking statements may turn out to be wrong
or be affected by inaccurate assumptions we might make or by known
or unknown risks and uncertainties. These forward-looking
statements are subject to risks and uncertainties including risks
related to our ability to maintain regulatory approval of Twirla,
the ability of Corium to produce commercial supply in quantities
and quality sufficient to satisfy market demand for Twirla, our
ability to successfully commercialize Twirla, the accuracy of our
estimates of the potential market and the market demand for Twirla,
regulatory and legislative developments in the United
States and foreign countries, our ability to obtain and
maintain intellectual property protection for Twirla, our strategy,
business plans and focus, the effects of the COVID-19 pandemic on
our operations and the operations of third parties we rely upon as
well as on our potential customer base, our ability to meet or
exceed the revenue thresholds necessary to permit us to access the
remaining amounts available under our existing debt financing from
Perceptive Advisors and the other risks set forth in our filings
with the U.S. Securities and Exchange Commission, including
our Annual Report on Form 10-K and our Quarterly Reports on Form
10-Q. For all these reasons, actual results and developments
could be materially different from those expressed in or implied by
our forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements, which are made
only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Contact: Matt RileyHead of Investor
Relations & Corporate
Communicationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2024 to May 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to May 2024